AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05447689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative-Mind-Body Skills Group
Description: Integrative-Mind-Body Skills Group (I-MBS-G) is an 8-week group that teaches skills to build inner resources for effective mood management. This group incorporates a holistic approach to wellness through meditation and mindfulness practices, guided imagery, breath and body awareness, relaxation techniques, self-reflection, and mindfulness-based cognitive-behavioral skills. Mind-body approaches have demonstrated effectiveness in reducing stress mood symptoms and improving quality of life.
Study NCT04764721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET-CT
Description: Enrolled patients in Neurocog-Covid will receive a 18F-FDG PET-CT
Study NCT06024187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold dissection
Description: The subcutaneous flap dissection was performed with a scissor in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally. Our tumescent technique utilizes a solution made by mixing 0.2ml of epinephrine with 250 ml of 0.9% Sodium Chloride solution to create a 1‰ ratio. 150ml to 150ml of the solution was injected into the subcutaneous tissue of the operated breast with a 20-gauge spinal needle to establish a bloodless plane. The septa between the skin flap and parenchyma then was dissected using a scissor.
Study NCT06024187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery Dissection
Description: The subcutaneous flap dissection was performed with electrocautery in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally.
Study NCT05631262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: Subjects of Cohot 1-5 and Part II Test group will receive SKB264 monotherapy
Study NCT05834049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Parental Presence on Induction of Anesthesia
Description: Apple Inc's FaceTime™ video application will be used when the child is taken to the operating room
Study NCT05834049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Preoperative midazolam (0.5 mg/kg of oral midazolam with a maximum dose of 20mg) will be given unless medically contraindicated.
Study NCT05398016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-intensity intervention for anxiety
Description: Brief (4-6 weekly 30-min sessions) delivery of a structured behavioral treatment for mild-to-moderate anxiety. Treatment will be based on principles of cognitive behavioral therapy (CBT).
Study NCT05956847 — intervention group
Intervention type: PROCEDURE
Intervention: gastroscopy
Description: When performing gastroscopy, the endoscopist will perform a biopsy based on the condition of gastric mucosal lesions, with one specimen retained and the remaining specimens subjected to pathological examination
Study NCT06320704 — intervention group
Intervention type: DEVICE
Intervention: Digital occlusal adjustment using Occulosense digital device
Description: Digital occlusal adjustment of mandibular complete denture using Occulosense digital device
Study NCT05444738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral lollipop with oxytocin (24IU)
Description: Immediately before drug administration, a blood sample (5ml) is collected. For drug administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after drug administration.
Study NCT05444738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral lollipop with placebo
Description: Immediately before drug administration, a blood sample (5ml) is collected. For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after placebo administration.
Study NCT05531552 — intervention group
Intervention type: DRUG
Intervention: clinical pharmacy application
Description: assessment clinical pharmacist in management of CAD and ICU patients.
Study NCT05631262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Part II Control group will receive docetaxel monotherapy.
Study NCT05573698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT-216
Description: DT-216 will be administered by intravenous (IV) injection
Study NCT05573698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered by intravenous (IV) injection
Study NCT06095141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2, ivgtt, 30 min, D1, 8. The administration of other chemotherapeutic agents including gemcitabine, nab-paclitaxel, fluorouracil, irinotecan, capecitabine is applied according to the National Comprehensive Cancer Network (NCCN) guideline. PARP inhibitor will be recommended to patients with platinum-sensitive metastatic PDAC after six months of cisplatin based regimen.
Study NCT04874532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Paramedic Program
Description: Patients will be seen for a 1-hr in person evaluation and follow-up will be determined on an individual basis based on patient need. During each visit, CPs will perform health status and social determinants of health assessments, physical exam, medication review/counseling, and goal setting/review.
Study NCT04874532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Material
Description: Participants will be provided with a diabetes resource card, which will provide a list of clinic and community-based diabetes resources, along with a diabetes education packet, which will include information on diabetes self-management, healthy diet, physical activity, glucose self-monitoring, and hypoglycemia.
Study NCT04874532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Material
Description: Participants will be provided with a diabetes resource card, which will provide a list of clinic and community-based diabetes resources, along with a diabetes education packet, which will include information on diabetes self-management, healthy diet, physical activity, glucose self-monitoring, and hypoglycemia.
Study NCT04768166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat 100 MG
Description: 100mg/TID in 4w then 200mg/TID in 8 w
Study NCT05317013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: CBD
Study NCT05317013 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06118645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab combined +paclitaxel (albumin-bound)
Description: 1. In the safe induction phase6 subjects will receive cadonilimab (10mg/kg, Q3W, intravenous infusion, up to 2 years) and paclitaxel (albumin-bound type)(125 mg/m2,Days1, 8,Q3w, intravenous infusion, up to 8 cycles).~2. If the safety and tolerability are good, and the initial efficacy signal is observed, the extended enrollment phase will enter the extended enrollment phase of drug administration and the safety introduction phase
Study NCT05335252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: 5mg 2x daily for 7 days
Study NCT05335252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 caplet 2x daily for 7 days
Study NCT06395116 — intervention group
Intervention type: OTHER
Intervention: Denture base material
Description: Denture base material constructed with different techniques for completely edentulous populations
Study NCT04597294 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FLOT + HIPEC + Surgery
Description: HIPEC with irinotecan after 4 doses of preoperative FLOT chemotherapy
Study NCT05704153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym 1Hz
Description: Transcutaneous auricular vagus nerve stimulation of 1Hz
Study NCT05704153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym 30Hz
Description: Transcutaneous Auricular Vagus Nerve Stimulation of 30Hz
Study NCT04689841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vojta Therapy
Description: Reflex locomotion is activated by the reflexogenic pathway. In context with reflex locomotion, the term reflex does not represent the mode of neuronal control, but rather refers to defined, automatic and always equal motor responses produced by external stimuli, applied therapeutically.
Study NCT04689841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In the control group, a placebo intervention is administered, similar to an experimental intervention
Study NCT05704153 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Sham stimulation
Study NCT04941690 — intervention group
Intervention type: OTHER
Intervention: A questionnaire method was used.
Description: The questionnaire included general population information, International Index of Sexual Function-5 (IIEF-5), Premature Ejaculation Diagnostic Tool (PEDT), General Anxiety Disorder-7 and CPSI.
Study NCT05831345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Hydrochloride
Description: Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
Study NCT05831345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil Citrate
Description: Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
Study NCT04713579 — intervention group
Intervention type: OTHER
Intervention: No intervention - observational study
Description: There is no intervention in this study as it is purely observational.
Study NCT05279105 — intervention group
Intervention type: BEHAVIORAL
Intervention: Program support
Description: The intervention to be evaluated in this study is program design and selection considerations by humanitarian organisations. It will comprise of factors that motivate organisations to chose certain delivery models in providing health care in conflict-affected settings
Study NCT06327620 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Daivobet ointment, topical steroids
Description: Daivobet Ointment: This intervention involves the topical application of Daivobet ointment, which is a combination of calcipotriol and betamethasone. The application is to be done three times daily for four weeks.~Topical Steroid: This intervention entails the topical application of a steroid ointment three times daily for four weeks. The specific steroid and its details are not disclosed in the provided information.
Study NCT06327620 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet ointment, topical steroids
Description: Daivobet Ointment: This intervention involves the topical application of Daivobet ointment, which is a combination of calcipotriol and betamethasone. The application is to be done three times daily for four weeks.~Topical Steroid: This intervention entails the topical application of a steroid ointment three times daily for four weeks. The specific steroid and its details are not disclosed in the provided information.
Study NCT04969341 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT04969341 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT04914117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC118 for injection
Description: RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.
Study NCT04597294 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FLOT + Surgery
Description: Perioperative FLOT chemotherapy (4 doses before and 4 doses after gastrectomy) and surgery
Study NCT05341297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentKIT
Description: The intervention is structured in 9 modules through which parents learn to identify and manage their children's anxiety and depressive symptoms. The Internet intervention is guided by two psychotherapists under supervision training in Cognitive Behavioral Therapy, trained by the first author on the treatment protocol.
Study NCT04724044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tablets
Description: Oral tablets of similar appearance to active study drug
Study NCT04724044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Oral tablets of 500mg of clarithromycin
Study NCT05805735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face care product (Eye cream)
Description: The test material(s) will be cosmetic products to be applied around the eye region on both sides of the face daily. The test product will be applied twice daily in the morning and in the evening by the subjects
Study NCT06406946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lion's mane blend
Description: 1.8 gram per day of lions mane, consisting of 3 x 600mg capsules
Study NCT06406946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lion's mane and reishi blend
Description: 1.8 gram per day of lions mane and reishi blend, consisting of 3 x 600mg capsules
Study NCT06406946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.8-gram microcrystalline cellulose placebo powder, 3x600mg capsules
Study NCT05387538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-layer Duct-to-mucosa Pancreaticojejunostomy
Description: To create the anterior suturing layers, double needles with a 4/0 or 3/0 Prolene line will be used; one side of the needles will be inserted from the anterior inner side of the pancreatic duct and out through the ventral parenchyma of the pancreatic stump to the anterior surface of the pancreas about 3 cm from the cut edge. The other side of the needles will be started from the inner side of the jejunum lumen, then pushed through the subserosa and seromuscular region, and out from the posterior surface of the bowel but its done after completion of the posterior layer. The posterior suturing layer will be treated in the same manner. An internal pancreatic duct stent will be used
Study NCT05387538 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-layer Duct-to-mucosa Pancreaticojejunostomy
Description: The same double needle and 4/0 or 3/0Prolene line will be used. First, the region approximately 1.0 cm from the cutting edge of the pancreatic remnant will be freed; then, the posterior surface of the pancreatic remnant will be sutured to the seromuscular layer of the jejunum using the interrupted suturing method. The jejunum will be brought closer to the stump of the pancreas, and a hole of similar diameter to the main pancreatic duct will be made on the jejunum near the entrance of the main pancreatic duct. The posterior wall of the jejunum near the hole will be sutured to the posterior wall of the pancreatic duct using the interrupted suturing method with Prolene line, and a suitable internal pancreatic duct stent will used . The interior side of the jejunum and pancreas will be sutured using the same method. Then, the anterior surface of the pancreatic remnant and the seromuscular layer of the jejunum will be tightly sutured using the interrupted method.
Study NCT00761488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® Toric IOL
Description: Implanted into the study eye
Study NCT05577026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention and prescription feedback
Description: Brief educational intervention and patient and provider materials regarding prescription of opioids. Subsequent feedback on clinic prescription of opioids over 12 months.
Study NCT05577026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General information on treatment guidelines
Description: Written information on guidelines and recommendations regarding prescription of opioids.
Study NCT06005909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cawthorne-Cooksey Exercises
Description: A- Head and Eye Movements While Lying and Sitting:~1. While keeping your head still, look up and then down again.~2. Look from side to side while keeping your head still.~3. Extend your hand at arm's length, draw your fingers towards your nose while focusing your eyes on your fingers.~4. With eyes open, slowly turn your head from side to side.~5. Turn your head from side to side quickly.~6. With eyes open, slowly move your head up and down.~7. Move your head up and down quickly.~8. Repeat items 4,5,6 and 7 with your eyes closed.~B-Head and Body Movements While Sitting:~1. Place an object on the floor in front of your feet, reach out to pick it up, then upright return to your position. Looking down while picking up the item, then Remind you to look up when trying to fix it.~2. Lean forward and move the object forward and back under your knees. C- Standing Exercises~1-Get from a sitting position to a standing position and sit down again. 2-Repeat this with your eyes closed.
Study NCT06005909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Hippotherapy Exercises
Description: From the patient on the mechanical hippotherapy device;~* Maintaining trunk balance while raising both hands above head,~* Maintaining trunk balance while opening the arms next to the trunk,~* Maintaining trunk balance while extending the arms back and forth with successive movements,~* Maintaining trunk balance with hands clasped behind the waist,~* The arms are open to both sides, while transferring the weight ball from one hand to the other, it is requested to maintain the body balance.
Study NCT06465784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde and Antegrade Ureteroscopic Laser Lithotripsy
Description: Comparison Between Retrograde and Antegrade Ureteroscopic Laser Lithotripsy for Management of Medium Sized Proximal Ureteral Stones: A Randomized Prospective Study
Study NCT01237925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine 1% gel
Description: Small amount applied over the lesion twice a day for 7 days
Study NCT04758598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Selective Laser Trabeculoplasty (DSLT)
Description: DSLT employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
Study NCT04758598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser Trabeculoplasty (SLT)
Description: SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
Study NCT04950205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalant product
Description: propofol plus 1% sevoflurane after open Carotid artery until the end of surgery
Study NCT01237925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine 1% cream
Description: Small amount applied over the lesion twice a day for 7 days
Study NCT05099536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D011-08
Description: participants will receive 15mg (starting dose)intravenous drop of 3D011-08,All subjects in each cohort will receive a single dose of 3D011-08 first, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive doses on 1,3,5day of each week (28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first.Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RPTD).
Study NCT04532073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eurythmy Therapy
Description: A mindfulness-oriented movement therapy
Study NCT04532073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: A martial art developed in China, which in recent times is often regarded as a system of movement theory or gymnastics
Study NCT04532073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Treatment process that a clinician should follow for a certain type of patient